Lunit Presents Research Abstract at European Society of Radiology Congress

[Asia Economy Reporter Chunhee Lee] Medical artificial intelligence (AI) company Lunit announced on the 11th that it will participate in the 'European Congress of Radiology 2022 (ECR 2022)' held in Vienna, Austria from the 13th to the 17th.

At this ECR, Lunit plans to present five research abstracts related to its breast mammography image analysis solution 'Lunit Insight MMG' and chest X-ray image analysis solution 'Lunit Insight CXR,' both of which have obtained European CE certification. ECR is the largest radiology conference in Europe, attended by radiology specialists and medical device company representatives worldwide. It is considered one of the two largest radiology conferences globally, alongside the Radiological Society of North America (RSNA).

Regarding Lunit Insight MMG, they will present research results proving that a new AI imaging biomarker can predict breast cancer occurrence within five years more accurately than the existing breast cancer prediction model (BCSC), even when no cancer is currently detected in mammography exams. They will also present two joint studies conducted with the University of Cambridge in the UK. Both parties plan to present research findings at the conference showing that Lunit Insight MMG can assist in detecting 'interval cancer' occurring between mammography screening intervals.

With the University Hospital Basel in Switzerland, they will present research abstracts related to Lunit Insight CXR. The collaboration confirmed a high accuracy of 97.3% in interpreting medical images using Lunit Insight CXR. The reading time also decreased by about 40%, from 23.2 seconds without AI to 14.1 seconds with AI assistance.

Additionally, results from nine domestic COVID-19 treatment centers using Lunit Insight CXR to predict the prognosis of COVID-19 patients will be presented. The study showed that combining Lunit Insight CXR with clinical data improved the prediction of prognosis such as intensive care unit admission rates and in-hospital mortality, as well as the need for additional interventions like oxygen supplementation and extracorporeal membrane oxygenation (ECMO).

Seobeom Seok, CEO of Lunit, said, "By introducing Lunit’s differentiated AI image analysis solution technology at this ECR conference, we will be able to accelerate our global market expansion, including Europe." He added, "Based on the proven technology at the conference, we plan to continuously expand partnerships with global healthcare companies and medical institutions to steadily increase our global market share."

This content was produced with the assistance of AI translation services.